(5-Bromo-7-chloro-2,3-dihydro-1-benzofuran-2-yl)methylcarbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: (5-Bromo-7-chloro-2,3-dihydro-1-benzofuran-2-yl)methylcarbamic acid
• 英文别名: (5-bromo-7-chloro-2,3-dihydro-1-benzofuran-2-yl)methylcarbamic acid
• 化学式: C₁₀H₉BrClNO₃
• 分子量: 306.54
• InChiKey: DHLWUPIYSCHODA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] MULTICYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS MULTICYCLIQUES ET LEURS UTILISATIONS
  申请人：KARYOPHARM THERAPEUTICS INC

  公开号：WO2017117447A1

  公开（公告）日：2017-07-06

  The present invention relates to multicyclic compounds containing a urea or a guanidine moiety, or pharmaceutically acceptable salts or compositions thereof represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof and pharmaceutical comopositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disesase) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

  本发明涉及含有脲基或胍基部分的多环化合物，或其结构式（IA）所代表的药学上可接受的盐或组合物，或其药学上可接受的盐，以及包含这些多环化合物的药物组合物。该发明还涉及一种治疗癌症（如淋巴瘤，如袖珍细胞淋巴瘤）、神经退行性疾病、炎症性疾病或免疫系统疾病（如T细胞介导的自身免疫疾病）的方法，该方法包括向需要的受试者施用本发明化合物的治疗有效量，或其药学上可接受的盐，或包含本发明化合物的组合物，或其药学上可接受的盐。
• MULTICYCLIC COMPOUNDS AND USES THEREOF
  申请人：Karyopharm Therapeutics Inc.

  公开号：US20190016710A1

  公开（公告）日：2019-01-17

  The present invention relates to multicyclic compounds containing a urea or a guanidine moiety, or pharmaceutically acceptable salts or compositions thereof represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

  本发明涉及多环化合物，其含有脲或胍基团，或其药学上可接受的盐或组成物，其结构式表示为（IA），或其药学上可接受的盐，以及包含该多环化合物的药物组合物。本发明还涉及一种治疗癌症（例如淋巴瘤，如袍细胞淋巴瘤）、神经退行性疾病、炎症性疾病或免疫系统疾病（例如T细胞介导的自身免疫疾病）的方法，该方法包括向需要治疗的受体中注射本发明化合物的治疗有效量，或其药学上可接受的盐，或包含本发明化合物的组合物，或其药学上可接受的盐。
• Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof
  申请人：KARYOPHARM THERAPEUTICS INC.

  公开号：US20160221994A1

  公开（公告）日：2016-08-04

  The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

  本发明通常涉及取代的2,3-二氢苯并呋喃基化合物，更具体地涉及由结构式（I）表示的化合物，或其药学上可接受的盐，在此变量的定义和描述中。本发明还包括合成和使用结构式（I）的化合物，或其药学上可接受的盐或组合物，例如在治疗癌症（例如曼托细胞淋巴瘤）和其他疾病和障碍中。
• Multicyclic compounds and uses thereof
  申请人：Karyopharm Therapeutics Inc.

  公开号：US10858347B2

  公开（公告）日：2020-12-08

  The present invention relates to multicyclic compounds containing a urea or a guanidine moiety, or pharmaceutically acceptable salts or compositions thereof represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

  本发明涉及含有脲基或胍基的多环化合物，或由结构式(IA)表示的其药学上可接受的盐或组合物，或其药学上可接受的盐，以及包含多环化合物的药物组合物。本发明还涉及一种治疗有需要的受试者的疾病或紊乱的方法，该疾病或紊乱选自癌症（如淋巴瘤，如套细胞淋巴瘤）、神经退行性疾病、炎症性疾病或免疫系统疾病（如T细胞介导的自身免疫性疾病）。该方法包括向有需要的受试者施用治疗有效量的本发明化合物或其药学上可接受的盐，或包含本发明化合物或其药学上可接受的盐的组合物。
• SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF
  申请人：Karyopharm Therapeutics, Inc.

  公开号：EP2925750A1

  公开（公告）日：2015-10-07